<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-40 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-40</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-40</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of the role of older age groups (older children, adolescents, adults) in poliovirus transmission in Pakistan, including evidence for or against their involvement, study types, age group definitions, key findings, vaccination status, and any interventions or counterpoints.</div>
                <p><strong>Paper ID:</strong> paper-107f3b8ca958869051b9ffdc0644293dae2ef254</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/107f3b8ca958869051b9ffdc0644293dae2ef254" target="_blank">Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic</a></p>
                <p><strong>Paper Venue:</strong> Vaccine</p>
                <p><strong>Paper TL;DR:</strong> A stochastic, geographically structured mathematical model of cVDPV2 transmission which captures both mucosal and humoral immunity separately and allows for reversion of serotype-2 oral polio vaccine (OPV2) virus to cVV2 following vaccine administration demonstrated ability to stop the cV DPV2 outbreak (with low risk of reverted Sabin-2 spread) by February 2021.</p>
                <p><strong>Cost:</strong> 0.001</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <p class="empty-note">No extracted data.</p>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <p class="empty-note">No potentially relevant new papers extracted.</p>
        </div>

        </div>

    </div>
</body>
</html>